Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

ZymoGenetics’ Atacicept Will Enter Phase II/III For Lupus Nephritis In Q4

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Company and partner Merck Serono also are working with FDA to finalize protocol for study in general systemic lupus erythematosus.

You may also be interested in...



HGS Follows Its Single-Cytokine BLISS In Lupus

Company bets BLyS specificity will beat ZymoGenetics’ dual approach in Phase III.

HGS Follows Its Single-Cytokine BLISS In Lupus

Company bets BLyS specificity will beat ZymoGenetics’ dual approach in Phase III.

Merck Serono Drops Diabetes Investment After Portfolio Review

German biopharma seeks licensing partners for diabetes treatments now in development while firm focuses R&D on cancer, other indications.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS065308

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By